pylori , Blastocystis hominis , yeast overgrowth , reactivated Epstein-Barr virus , and small intestinal bacterial overgrowth ( SIBO )
Notably, the Roux-en-Y procedure has a greater impact on MASLD than the other procedures, improving or resolving steatosis in 91% of patients and liver fibrosis in 31%
[Google Scholar] 8.Long LH, Lan ANB, Hsuan FTY, Halliwell B
Since that time, GP-1s have gained FDA approval for the treatment of cardiovascular disease, obesity, sleep apnea and kidney disease
Some individuals naturally experience milder digestive disruption because their genetic profile makes them less reactive to GLP-1 agonist dosing